Convergence Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.2M Buy
8,507
+4,147
+95% +$4.24M 0.81% 35
2026
Q1
$4.01M Sell
4,360
-96
-2% -$97.3K 0.43% 44
2025
Q4
$4.79M Buy
4,456
+58
+1% +$55.5K 0.7% 34
2025
Q3
$3.36M Buy
4,398
+132
+3% +$98.2K 0.5% 38
2025
Q2
$3.33M Buy
4,266
+291
+7% +$226K 0.57% 38
2025
Q1
$3.28M Buy
3,975
+323
+9% +$269K 0.64% 34
2024
Q4
$2.82M Buy
3,652
+56
+2% +$46.4K 0.56% 32
2024
Q3
$3.19M Buy
3,596
+299
+9% +$269K 0.68% 30
2024
Q2
$2.99M Buy
+3,297
New +$2.64M 0.79% 27

Other funds holding LLY

Convergence Financial's LLY Position: Q2 2026 in Review

Convergence Financial increased its Eli Lilly (LLY) stake by 95% in Q2 2026, buying an estimated $4.24M and bringing the position to 8,507 shares worth $10.2M. The position accounts for 0.81% of the portfolio, ranked #35.

Convergence Financial first reported a position in LLY in Q2 2024 and has held it in 9 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Convergence Financial held 8,507 shares of Eli Lilly worth $10.2M as of Q2 2026.
  • Convergence Financial bought 4,147 Eli Lilly shares in Q2 2026, an estimated $4.24M.
  • Eli Lilly made up 0.81% of Convergence Financial's portfolio in Q2 2026, its #35 holding.
  • Convergence Financial first reported a position in Eli Lilly in Q2 2024 and has held it in 9 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Convergence Financial's 13F filing for Q2 2026, filed 5 Aug 2026.